Gahyun Gim, MD : Research

Cancer Specialist (Oncologist), Hematology and Oncology Specialist

4.8

Provider profile Menu

Active clinical trials

Study of Rilvegostomig or Durvalumab +Chemo for 1st Line Tx of BTC (ARTEMIDE-Biliary02) (AB02)

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

Investigator: Gahyun Gim
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

My publications

6 publications

2026

Total Neoadjuvant Therapy with FOLFOX Followed by Short-Course Radiation in Locally Advanced Rectal Cancer-An Alternative Approach Evaluated in a Single-Center Clinical Trial.

Journal of clinical medicine

PubMed • Publisher's site

2022

Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review.

The oncologist

PubMed • Publisher's site

2022

Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.

The oncologist

PubMed • Publisher's site

2021

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy.

Heliyon

PubMed • Publisher's site

2021

Blood transfusions may adversely affect survival outcomes of patients with lung cancer: a systematic review and meta-analysis.

Translational lung cancer research

PubMed • Publisher's site

Active clinical trials

My publications

Filter publications

Total Neoadjuvant Therapy with FOLFOX Followed by Short-Course Radiation in Locally Advanced Rectal Cancer-An Alternative Approach Evaluated in a Single-Center Clinical Trial.

Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review.

Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy.

Blood transfusions may adversely affect survival outcomes of patients with lung cancer: a systematic review and meta-analysis.